Agilent, PTC Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Portfolio Pulse from Lisa Levin
PTC Therapeutics' shares dipped 21.3% after its MOVE-FA trial failed to meet its primary endpoint, while Agilent Technologies' shares declined 8.8% after cutting its FY23 revenue outlook. Global Net Lease, Apollomics, Genesis Growth Tech Acquisition Corp, MorphoSys, and Prudential also experienced pre-market losses.
May 24, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agilent Technologies' shares declined 8.8% after the company cut its FY23 revenue outlook.
Agilent's decision to cut its FY23 revenue outlook indicates potential challenges in the company's growth, which may negatively impact its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Apollomics' shares dropped 8% in pre-market trading.
Apollomics' shares dropped 8% in pre-market trading, which may indicate negative sentiment or news surrounding the company, potentially impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Genesis Growth Tech Acquisition Corp's shares fell 4.9% in pre-market trading after gaining 7% on Tuesday.
Genesis Growth Tech Acquisition Corp's shares fell 4.9% in pre-market trading, potentially due to profit-taking after a 7% gain on Tuesday, which may impact its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Global Net Lease's shares fell 10.4% in pre-market trading after posting a decline in quarterly sales.
The decline in Global Net Lease's quarterly sales may indicate potential challenges in the company's performance, which could negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
MorphoSys' shares dropped 4.4% in pre-market trading despite recently reporting better-than-expected quarterly results.
MorphoSys' shares dropped 4.4% in pre-market trading, which may indicate negative sentiment or news surrounding the company, potentially impacting its stock price in the short term despite better-than-expected quarterly results.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
PTC Therapeutics' shares dipped 21.3% after its MOVE-FA trial of vatiquinone failed to meet its primary endpoint.
The failure of the MOVE-FA trial to meet its primary endpoint is a significant setback for PTC Therapeutics, which will likely negatively impact its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Prudential's shares dropped 3% in pre-market trading.
Prudential's shares dropped 3% in pre-market trading, which may indicate negative sentiment or news surrounding the company, potentially impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 100